BPC February 15 update

Editas (EDIT) scores patent win - shares +29%; Ardelyx (ARDX) jumps on tenapanor data; Acura (ACUR) delist to OTC

Price and Volume Movers

The US Patent and Trademark Office ruled today that patents awarded to the Broad Institute CRISPR-Cas9 technology will remain. This follows a patent battle between Broad and the University of California over rights to the technology. News of the patent win saw shares of Editas Medicine Inc (NASDAQ:EDIT) close up $29% to $24.30. In 2014, the company formed a license agreement with the Broad Institute to access intellectual property and technology related to the CRISPR/Cas9 genome editing systems. On the other side, shares of Crispr Therapeutics (NASDAQ:CRSP) closed down 8% to $15.90 while shares of Intellia Therapeutics Inc (NASDAQ:NTLA) dropped 9% to $12.50, paring earlier losses in the the early afternoon session. Both companies were founded using CRISPR/Cas9 biology based on research carried out at the University of California.

Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) announced after hours that its shares will begin to trade on the OTCQB Market under the same ticker from February 23, 2017. Shares are currently down 34% to $1.16.

Ardelyx, Inc. (NASDAQ: ARDX) announced that it met the primary endpoint in its Phase 3 trial of tenapanor for the treatment for hyperphosphatemia in patients with end-stage renal disease (ESRD) who are on dialysis. The company noted a 39% diarrhea rate which resulted in 7.8% of patients discontinuing the trial, lower than its previous Phase 2 trial. Shares rose 14% to $13.00.

Auris Medical Holding AG (NASDAQ: EARS) announced the pricing of its previously announced public offering of 10m shares and 10m warrants, with each warrant entitling its holder to purchase 0.70 of a common share (one unit).  The offering will be priced at $1 per unit for gross proceeds of $10m. Shares closed down 19% to $0.934.

Celsion Corporation (NASDAQ:CLSN) also announced the pricing of a public offering with expected total gross proceeds of approximately $5m. The offering, priced at $0.23 per share included warrants to purchase 0.75 of a share of common stock, at an exercise price of $0.23 per share. Shares closed down 33% to $0.22.

Evoke Pharma, Inc. (NASDAQ:EVOK) shares spiked at the open and closed up 30% to $3.40 following notice that it has received a letter from FDA exempting its late stage product, Gimoti from a Human Factors (HF) Validation study requirement prior to submission of a New Drug Application (NDA), slated for filing by the end of 2017.


Other major price movers:

ADVANCERS:

Zosano Pharma Corp (NASDAQ:ZSAN): $2.85; +41%.

Novan Inc (NASDAQ:NOVN): $6.44; +34%.

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO): $0835; +15%.

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA): $3.22; +14%

Novavax, Inc. (NASDAQ:NVAX): $1.62; +14%.


DECLINERS:

Delcath Systems, Inc.(NASDAQ:DCTH): $0.156; +21%.

Galectin Therapeutics Inc (NASDAQ:GALT): $1.47; -18%.

Bellerophon Therapeutics Inc (NASDAQ:BLPH): $0.90; -12%.

Neothetics Inc (NASDAQ:NEOT): $1.41; -10%.

BioDelivery Sciences International, Inc.(NASDAQ:BDSI): $1.90; -7%.


 

Full pipeline updates:

Pipeline Database Updates

Drug Stage Catalyst

ALKS
ALKS 5461
Major depressive disorder

Phase 3 Phase 3 data from first two trials did not meet their endpoints. FORWARD-5 data, the third of three trials did meet endpoints - October 2016. NDA to be filed 2017.

ARDX
Tenapanor
Hyperphosphatemia in end-stage renal disease (ESRD) patients

Phase 3 Phase 3 released February 15, 2017 - primary endpoint met. Second Phase 3 trial to be initiated mid-2017.

DCTH
Melphalan Hepatic Delivery System (Melphalan HDS)
Hepatocellular carcinoma (HCC) - cancer

Phase 3 Phase 3 initiated February 2016. Ongoing as of November 2016. Interim safety analysis due 2H 2017.

EVOK
Gimoti - EVK-001
Female diabetic gastroparesis

Phase 3 Phase 3 data released July 2016. Primary endpoint not met. However, the company noted December 15, 2016 that following discussions with FDA regarding possible NDA submission, no new efficacy or safety study would be required, if bioequivalence criteria were met in a pharmacokinetic (PK) trial. NDA filing to be submitted by the end of 2017.

MNOV
MN-166
Progressive multiple sclerosis (progressive MS)

Phase 2b Phase 2b final data due 2H 2017.

NVCR
Tumor Treating Fields (TTFields) LUNAR
Non-small cell lung cancer (NSCLC)

Phase 3 Phase 3 commencement of enrollment announced February 15, 2017.

PRTA
PRX003
Psoriatic Arthritis

Phase 1b Phase 1b data due 3Q 2017.

PRTA
NEOD001 VITAL
AL Amyloidosis

Phase 3 Phase 3 enrollment to be completed by 2Q 2017.

PRTA
NEOD001 PRONTO
Previously-treated patients with AL amyloidosis and persistent cardiac dysfunction

Phase 2b Phase 2b data due 2Q 2018.

PRTA
PRX002
Parkinson's disease

Phase 2 Phase 2 planned for 2017.

SBPH
SB 9200
Hepatitis B (HBV)

Phase 2a Phase 2a data due 2Q 2017.

VNDA
HETLIOZ (tasimelteon) - pediatric formulation
Insomnia

Phase 3 PK trial to be initiated 2018.

VNDA
HETLIOZ (tasimelteon)
Smith-Magenis Syndrome

Phase 3 Phase 3 initiated 4Q 2016. Data due 2018.

VNDA
VLY-686 (tradipitant)
Chronic pruritus in patients with atopic dermatitis

Phase 2 Phase 2 data due in mid-2017.

VNDA
HETLIOZ (tasimelteon)
Jet Lag Disorder

Phase 2 Phase 2 data due in 2H 2017.